Moving forward with Takeda's live chimeric tetravalent dengue vaccine
Several decades of dengue vaccine research have shown how challenging it is to develop a highly efficacious vaccine that protects against all four dengue serotypes (DENV-1–4) for people of all ages. In light of the rapidly rising incidence of dengue virus infection, now estimated to affect about 100...
Saved in:
Main Author: | Wilder-Smith, Annelies |
---|---|
Other Authors: | Lee Kong Chian School of Medicine (LKCMedicine) |
Format: | Article |
Language: | English |
Published: |
2017
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/83617 http://hdl.handle.net/10220/42732 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
-
Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine
by: Wilder-Smith, Annelies, et al.
Published: (2016) -
Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines
by: Vannice, Kirsten S., et al.
Published: (2018) -
Dengue vaccines for travelers
by: Wilder-Smith, A., et al.
Published: (2011) -
Edging closer towards the goal of a dengue vaccine
by: Wilder-Smith, Annelies, et al.
Published: (2016) -
Update on Dengue: Epidemiology, Virus Evolution, Antiviral Drugs, and Vaccine Development
by: Wilder-Smith, A., et al.
Published: (2011)